|
Name |
(1R,2S,12R,15R)-1,2-dihydroxy-7-methoxy-12-(2-methylprop-1-enyl)-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-14,20-dione
|
Molecular Formula | C22H25N3O5 | |
IUPAC Name* |
(1R,2S,12R,15R)-1,2-dihydroxy-7-methoxy-12-(2-methylprop-1-enyl)-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-14,20-dione
|
|
SMILES |
CC(=C[C@@H]1C2=C([C@@H]([C@@]3(N1C(=O)[C@H]4CCCN4C3=O)O)O)C5=C(N2)C=C(C=C5)OC)C
|
|
InChI |
InChI=1S/C22H25N3O5/c1-11(2)9-16-18-17(13-7-6-12(30-3)10-14(13)23-18)19(26)22(29)21(28)24-8-4-5-15(24)20(27)25(16)22/h6-7,9-10,15-16,19,23,26,29H,4-5,8H2,1-3H3/t15-,16-,19+,22-/m1/s1
|
|
InChIKey |
CPHRCQUGNAGVIB-JWKLYUKHSA-N
|
|
Synonyms |
cyclotryprostatin A
|
|
CAS | NA | |
PubChem CID | 102379065 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 411.5 | ALogp: | 1.1 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 106.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 30 | QED Weighted: | 0.658 |
Caco-2 Permeability: | -5.152 | MDCK Permeability: | 0.00000552 |
Pgp-inhibitor: | 0.985 | Pgp-substrate: | 0.942 |
Human Intestinal Absorption (HIA): | 0.268 | 20% Bioavailability (F20%): | 0.348 |
30% Bioavailability (F30%): | 0.979 |
Blood-Brain-Barrier Penetration (BBB): | 0.101 | Plasma Protein Binding (PPB): | 74.46% |
Volume Distribution (VD): | 1.34 | Fu: | 13.14% |
CYP1A2-inhibitor: | 0.024 | CYP1A2-substrate: | 0.14 |
CYP2C19-inhibitor: | 0.383 | CYP2C19-substrate: | 0.825 |
CYP2C9-inhibitor: | 0.449 | CYP2C9-substrate: | 0.758 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.147 |
CYP3A4-inhibitor: | 0.519 | CYP3A4-substrate: | 0.928 |
Clearance (CL): | 5.202 | Half-life (T1/2): | 0.643 |
hERG Blockers: | 0.055 | Human Hepatotoxicity (H-HT): | 0.974 |
Drug-inuced Liver Injury (DILI): | 0.984 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.866 | Maximum Recommended Daily Dose: | 0.981 |
Skin Sensitization: | 0.168 | Carcinogencity: | 0.173 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.954 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001958 | 1.000 | D06YFA | 0.278 | ||||
ENC003265 | 0.837 | D0J4JM | 0.270 | ||||
ENC002064 | 0.769 | D0G8NJ | 0.268 | ||||
ENC003013 | 0.732 | D01TSI | 0.256 | ||||
ENC000837 | 0.673 | D0P0RX | 0.256 | ||||
ENC002274 | 0.636 | D02IQY | 0.255 | ||||
ENC002846 | 0.629 | D0H4JM | 0.254 | ||||
ENC005479 | 0.600 | D00XHD | 0.250 | ||||
ENC002260 | 0.595 | D0SP3D | 0.249 | ||||
ENC002042 | 0.563 | D09NNH | 0.249 |